Clopidogrel Resistance in Lower Extremity Arterial Disease
Author Information
Author(s): Burke Kerry A., McDermott John H., Wright Stuart J., Newman William G., Greaves Nicholas S.
Primary Institution: Manchester University NHS Foundation Trust
Hypothesis
Should CYP2C19 genetic testing be routinely implemented in patients prescribed clopidogrel to improve outcomes in lower extremity arterial disease?
Conclusion
Implementing a precision medicine strategy in vascular surgery could significantly enhance clinical outcomes for patients with lower extremity arterial disease.
Supporting Evidence
- CYP2C19 genetic testing can identify patients who may not respond well to clopidogrel.
- Patients with CYP2C19 loss of function alleles have higher risks of adverse outcomes when treated with clopidogrel.
- Genotype-guided therapy has been shown to improve clinical outcomes in cardiac and stroke medicine.
Takeaway
Some people don't respond well to a medicine called clopidogrel, which is used to help blood flow in their legs. Testing their genes can help doctors find better treatments for them.
Methodology
Narrative review of literature on CYP2C19 genetic testing and clopidogrel use in patients with lower extremity arterial disease.
Potential Biases
The studies are at risk of bias due to their design and small sample sizes.
Limitations
The studies reviewed are mostly small, single-center, and retrospective, limiting generalizability.
Participant Demographics
The review includes studies with diverse populations, including British Bangladeshi and Pakistani ancestry.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% CI, 1.75-14.25
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website